News

Beijing, China – March 25, 2026.  Pulmongene Ltd., a clinical-stage biotechnology company dedicated to pulmonary, fibrotic, and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PMG1015 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The designation supports the ongoing development of PMG1015, which will be […]

[Beijing, China] – January 19th, 2026. Pulmongene Ltd., a clinical-stage biotechnology company dedicated to pulmonary, fibrotic, and autoimmune diseases, today announced a significant milestone: the U.S. Food and Drug Administration (FDA) has cleared the IND application to initiate a Phase IIb clinical trial for PMG1015 on Jan 10, 2026. This approval greenlights a 52-week, randomized,

Beijing, China – September 2, 2025 – Pulmongene Ltd., a leading clinical-stage biotechnology company focused on discovering and developing innovative therapies for respiratory disorders and fibrotic diseases, today announced that its Phase 1b clinical trial data for PMG1015 have been selected for a presentation as a Late-Breaking-Abstract at the European Respiratory Society (ERS) International Congress

On July 5, 2023, Pulmongene Ltd. announced that its investigational drug PMG1015 has completed the first administration in a patient with idiopathic pulmonary fibrosis (IPF) at the China-Japan Friendship Hospital. This study is a multicenter, randomized, double-blind, placebo-controlled Phase Ib clinical trial aimed at evaluating the safety, tolerability, and pharmacokinetics of multiple doses of PMG1015

On February 17th, 2023 , Pulmongene Ltd. announced that the company’s investigational drug PMG1015 has been granted Orphan Drug Designation (ODD) for the indication of Idiopathic Pulmonary Fibrosis (IPF). The FDA’s orphan drug designation supports the development of medicines intended to treat rare diseases that affect fewer than 200,000 people in the United States. Products